长非编码RNAMAFG-AS1与癌症预后之间的相关性:一个元分析
Guangyao Lin1, Huicong Liu1, Jingyu Lin1
1Department of Gynecology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Frontiers in oncology
|December 22, 2023
概括
这一元分析显示,高MAFG-AS1表达与晚期癌症和低生存率有关. MAFG-AS1显示为预测恶性瘤预后的生物标志物具有前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 长非编码RNAs (lncRNAs) 越来越多地被认为是它们在癌症中的作用.
- MAF转录因子G反意义RNA1 (MAFG-AS1) 是最近发现的一种具有潜在预后价值的lncRNA.
- 之前对MAFG-AS1与癌症预后相关性的研究已经产生了不一致的结果.
研究的目的:
- 进行元分析以澄清MAFG-AS1在各种癌症中的临床病理和预后意义.
- 巩固有关MAFG-AS1表达水平和癌症患者结果的现有证据.
主要方法:
- 在六个电子数据库中进行了系统的文献搜索,用于调查MAFG-AS1表达和癌症预后的研究.
- 使用危险比率 (HRs) 和几率比率 (ORs) 来评估MAFG-AS1.1的预后值.
- 用GEPIA数据库进行MAFG-AS1表达在不同癌症类型中的额外验证.
主要成果:
- 分析包括15项研究,包括9种癌症类型的1187例病例.
- 高MAFG-AS1表达与晚期瘤阶段,较早的淋巴结转移,较差的瘤分化和降低整体存活率显著相关.
- 没有观察到显著的异质性或出版偏差. 通过GEPIA验证,发现MAFG-AS1在10种癌症类型中升高.
结论:
- 高MAFG-AS1表达与各种癌症的不良预后有很强的相关性.
- MAFG-AS1成为预测恶性瘤结果的潜在和有前途的生物标志物.
- 需要进一步的研究,以充分阐明MAFG-AS1在癌症进展中的作用.
相关概念视频
lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Cancer Survival Analysis
355
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
355
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Non-LTR Retrotransposons
11.5K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.5K


